On heels of pos­i­tive da­ta for AT­TR drug, Al­ny­lam looks to raise more cap­i­tal — near­ly $1B worth

A week af­ter pre­sent­ing pos­i­tive da­ta on its drug for treat­ing the heart fail­ure con­di­tion called transthyretin-me­di­at­ed amy­loi­do­sis (AT­TR) with car­diomy­opa­thy, Al­ny­lam wants to get …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER